Ribonucleic Acid (RNA) Editing Market Report 2025

The ribonucleic acid (RNA) editing market size has grown strongly in recent years. It will grow from $16.1 billion in 2024 to $17.55 billion in 2025 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to the rising demand for transient and reversible RNA editing methods, expanding applications in neurodegenerative disease research, increasing prevalence of rare and orphan diseases, growing interest in synthetic biology and bioengineering, and heightened academic and translational research activities.

The ribonucleic acid (RNA) editing market size is expected to see strong growth in the next few years. It will grow to $24.42 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to the rising prevalence of genetic disorders, expanding emphasis on personalized medicine, increasing applications in cancer therapy, advancements in delivery systems, and growing support from government and regulatory agencies. Major trends during this period include innovations in RNA editing platforms, progress in in vivo delivery technologies, advancements in sequencing and transcriptomics, development of transient gene modulation techniques, and expansion of synthetic biology applications.

The rising prevalence of genetic disorders is driving growth in the ribonucleic acid (RNA) editing market. Genetic disorders, caused by inherited or spontaneous mutations, are becoming more common partly due to increasing parental age, which raises the likelihood of chromosomal abnormalities. RNA editing enables treatment by correcting mutations at the RNA level, allowing cells to produce functional proteins without changing the underlying DNA. For example, as of May 2024, sickle cell disease affects approximately 100,000 people in the United States, illustrating the significant need for RNA-based therapeutic approaches.

Companies in the RNA editing market are advancing innovative approaches such as in vivo gene editing, which directly alters genes within living cells to correct disease-causing mutations. In April 2024, the Rett Syndrome Research Trust launched the MECP2 Editing Consortium to develop RNA and DNA editing therapies targeting the genetic causes of Rett syndrome. By combining expertise from six leading laboratories, the consortium aims to accelerate clinical development of precise, potentially curative treatments for this neurological disorder.

In May 2025, Rznomics Inc., a South Korea-based biopharmaceutical company, partnered with Eli Lilly and Company to develop RNA-editing therapies for sensorineural hearing loss. Rznomics is utilizing its trans-splicing ribozyme platform for early-stage research, while Eli Lilly manages later-stage development and global commercialization. This collaboration highlights the growing investment in RNA-editing technologies to deliver targeted therapies for genetic and rare diseases.

Major players in the ribonucleic acid (RNA) editing market are Moderna Inc., Arcturus Therapeutics Holdings Inc., CureVac AG, Beam Therapeutics Inc., EdiGene Inc., Ethris GmbH, Deep Genomics Incorporated, ProQR Therapeutics NV, ReCode Therapeutics, Capstan Therapeutics Inc., TriLink BioTechnologies, ADARx Pharmaceuticals Inc., Storm Therapeutics Limited, Ascidian Therapeutics Inc., Rznomics Inc., Airna Biotech S.L., hC Bioscience Inc., Korro Bio Inc., Shape TX, and Turn Biotechnologies.

North America was the largest region in the ribonucleic acid(RNA) editing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ribonucleic acid (RNA) editing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ribonucleic acid (RNA) editing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Ribonucleic acid (RNA) editing is a post-transcriptional mechanism that modifies the nucleotide sequence of RNA molecules after they are transcribed from deoxyribonucleic acid (DNA). These modifications can alter the structure or function of the resulting protein, thereby influencing gene expression and presenting potential therapeutic opportunities.

The primary types of RNA editing include messenger RNA (mRNA) modification, transfer RNA (tRNA) modification, and ribosomal RNA (rRNA) modification. Messenger RNA modification involves chemical alterations to mRNA molecules after transcription, such as methylation or nucleotide sequence changes. Common techniques include nucleotide insertion or deletion and deamination. These modifications have applications in treating conditions such as cancer, genetic disorders, and transient ailments.

The ribonucleic acid (RNA) editing market research report is one of a series of new reports that provides ribonucleic acid (RNA) editing market statistics, including the ribonucleic acid (RNA) editing industry's global market size, regional shares, competitors with the ribonucleic acid (RNA) editing market share, detailed ribonucleic acid (RNA) editing market segments, market trends and opportunities, and any further data you may need to thrive in the ribonucleic acid (RNA) editing market. This ribonucleic acid (RNA) editing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The ribonucleic acid (RNA) editing market consists of revenues earned by entities by providing services such as therapeutic ribonucleic acid (RNA) editing services, ribonucleic acid (RNA) editing delivery optimization, and bioinformatics and data analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The ribonucleic acid (RNA) editing market also includes sales of ribonucleic acid (RNA) editing therapeutics, diagnostic kits, and ribonucleic acid (RNA) editing delivery systems. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.